Bank CEOs meet with Trump to discuss Fannie Mae and Freddie Mac - Bloomberg
LONDON - Smith+Nephew (LSE:SN, NYSE: SNN), a leading global medical technology company, has announced that it will release its first quarter trading report for the period ending March 29, 2025, on Wednesday, April 30, 2025. The announcement, scheduled for 7.00 am BST (2.00 am EDT), will provide insights into the company’s performance at the start of the fiscal year.
Following the release of the trading report, Smith+Nephew will conduct a conference call for financial analysts at 8.30 am BST (3.30 am EDT). Further details regarding the call will be made available on the company’s website.
Smith+Nephew specializes in the development of medical technology aimed at the repair, regeneration, and replacement of soft and hard tissue. With a purpose stated as ’Life Unlimited’, the company strives to improve patient outcomes through its product offerings and technological advancements. Operating in approximately 100 countries, Smith+Nephew employs around 17,000 people worldwide and reported annual sales of $5.8 billion in 2024.
The company, which was founded in Hull, UK, in 1856, is part of the FTSE100 index and is publicly traded on both the London Stock Exchange (LON:LSEG) and the New York Stock Exchange under the tickers LSE:SN and (NYSE:SNN), respectively.
In its communication, Smith+Nephew also included forward-looking statements concerning expected revenue growth, trading profit margins, and market trends. However, these statements are subject to various risks and uncertainties that could cause actual results to differ materially from expectations.
The company’s forward-looking statements are based on information available as of the date of the statement and are qualified by cautionary language regarding the potential for change due to numerous factors, including market conditions, regulatory actions, and global economic influences.
This news article is based on a press release statement from Smith+Nephew. The information contained herein is intended to provide a factual report on the company’s upcoming announcement of its first quarter trading report and should not be considered an endorsement of the company’s performance or future prospects.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.